These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 34844976)

  • 21. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
    Abbosh C; Frankell AM; Harrison T; Kisistok J; Garnett A; Johnson L; Veeriah S; Moreau M; Chesh A; Chaunzwa TL; Weiss J; Schroeder MR; Ward S; Grigoriadis K; Shahpurwalla A; Litchfield K; Puttick C; Biswas D; Karasaki T; Black JRM; Martínez-Ruiz C; Bakir MA; Pich O; Watkins TBK; Lim EL; Huebner A; Moore DA; Godin-Heymann N; L'Hernault A; Bye H; Odell A; Roberts P; Gomes F; Patel AJ; Manzano E; Hiley CT; Carey N; Riley J; Cook DE; Hodgson D; Stetson D; Barrett JC; Kortlever RM; Evan GI; Hackshaw A; Daber RD; Shaw JA; Aerts HJWL; Licon A; Stahl J; Jamal-Hanjani M; ; Birkbak NJ; McGranahan N; Swanton C
    Nature; 2023 Apr; 616(7957):553-562. PubMed ID: 37055640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 23. Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC).
    Chen K; Zhao H; Shi Y; Yang F; Wang LT; Kang G; Nie Y; Wang J
    Clin Cancer Res; 2019 Dec; 25(23):7058-7067. PubMed ID: 31439586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
    Loupakis F; Sharma S; Derouazi M; Murgioni S; Biason P; Rizzato MD; Rasola C; Renner D; Shchegrova S; Koyen Malashevich A; Malhotra M; Sethi H; Zimmermann BG; Aleshin A; Moshkevich S; Billings PR; Sedgwick JD; Schirripa M; Munari G; Cillo U; Pilati P; Dei Tos AP; Zagonel V; Lonardi S; Fassan M
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34327297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
    Li Y; Mo S; Zhang L; Ma X; Hu X; Huang D; Lu B; Luo C; Peng H; Cai S; Sheng W; Peng J
    Eur J Cancer; 2022 Jul; 169():198-209. PubMed ID: 35636041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer.
    Peng M; Huang Q; Yin W; Tan S; Chen C; Liu W; Tang J; Wang X; Zhang B; Zou M; Li J; Su W; Wang L; Chin L; Yu F
    Front Oncol; 2020; 10():561598. PubMed ID: 33042842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
    Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
    BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [MinerVa: A high performance bioinformatic algorithm for the detection of minimal residual disease in solid tumors].
    Yang P; Zhang Y; Xia L; Mei J; Fan R; Huang Y; Liu L; Chen W
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2023 Apr; 40(2):313-319. PubMed ID: 37139763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients.
    Li H; Ma ZL; Li B; Pan YJ; Xiang JQ; Zhang YW; Sun YH; Hou T; Lizaso A; Chen Y; Li X; Hu H
    Cancer Med; 2021 Dec; 10(23):8377-8386. PubMed ID: 34664796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
    Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
    Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
    Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
    Pellini B; Chaudhuri AA
    J Clin Oncol; 2022 Feb; 40(6):567-575. PubMed ID: 34985936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    Lipsyc-Sharf M; de Bruin EC; Santos K; McEwen R; Stetson D; Patel A; Kirkner GJ; Hughes ME; Tolaney SM; Partridge AH; Krop IE; Knape C; Feger U; Marsico G; Howarth K; Winer EP; Lin NU; Parsons HA
    J Clin Oncol; 2022 Aug; 40(22):2408-2419. PubMed ID: 35658506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.
    Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J
    J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection.
    Xu Y; Cai J; Zhong K; Wen Y; Cai L; He G; Liao H; Zhang C; Fu S; Chen T; Cai J; Zhong X; Chen C; Huang M; Cheng Y; Pan M
    Front Oncol; 2023; 13():1119744. PubMed ID: 36959801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.
    Chaudhuri AA; Chabon JJ; Lovejoy AF; Newman AM; Stehr H; Azad TD; Khodadoust MS; Esfahani MS; Liu CL; Zhou L; Scherer F; Kurtz DM; Say C; Carter JN; Merriott DJ; Dudley JC; Binkley MS; Modlin L; Padda SK; Gensheimer MF; West RB; Shrager JB; Neal JW; Wakelee HA; Loo BW; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Dec; 7(12):1394-1403. PubMed ID: 28899864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.